Novartis wins new use for Afinitor; Pfizer's Revatio gets pediatric nod;

@FiercePharma: Garnier pledges active role on Actelion board. News | Follow @FiercePharma

> Novartis' cancer drug Afinitor won the FDA's nod for a rare type of pancreatic cancer that has few treatment options. News

> Salix Pharmaceuticals posted a quarterly profit that beat market estimates, helped by higher sales from its flagship drug Xifaxan, which is used to treat travellers' diarrhea. Item

> Pfizer's Revatio won approval from the European Commission for the treatment of pediatric patients 1 to 17 years old with pulmonary arterial hypertension. Article

> The Centers for Medicare & Medicaid Services overpaid for dozens of drugs in 2009 by an estimated $4.4 million, the HHS Inspector General said. Story

> Australia's federal government is ignoring its own growth forecasts for the Pharmaceutical Benefits Scheme and making policy decisions without an evidence base, says industry. Report

> Shares of Savient Pharmaceuticals slid after the company posted a wider quarterly loss that missed estimates, prompting an analyst to downgrade the stock. Article

> Vanda Pharmaceuticals said that its profit fell 74 percent in the first quarter as it booked sharply lower royalty revenue and no product sales. Item

> Dusa Pharmaceuticals stock surged after the company said sales of its Levulan Kerastick skin treatment grew strongly for the second consecutive quarter. News

> Aesthetic laser device maker Solta Medical said it received FDA approval for its new anti-aging treatment, Clear + Brilliant. Story

Biotech News

 @FierceBiotech: Struggling Intercell replaces its CEO. Item | Follow @FierceBiotech 

 @JohnCFierce: Pfizer may still do bolt-ons: "pain, or in women's health, or in the vaccine area, or in oncology" Follow @JohnCFierce

> CRO Health Decisions offers to share risks on adaptive trials. News 

> Florida's biotech industry continues to grow. Article 

> Report: GSK has no plans to sell HIV unit. Story 

> Crown raises $28.8M for oncology work. News 

And Finally... Among the millions of men tested for prostate cancer each year, an increasing number are getting sick from potentially lethal, drug-resistant infections. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.